1. Meaning and nature of the doctrine

The Artificial Endocrine Governance Doctrine is a proposed analytical framework for regulating technologies that artificially influence, replace, monitor, or control the human endocrine system. It is not, as far as established legal doctrine is concerned, a formally recognized standalone doctrine under Indian law or a universally accepted principle of international law.

The concept can be developed by applying established legal principles concerning medical-device regulation, pharmaceutical safety, informed consent, bodily integrity, privacy, negligence, product liability, and government accountability.

The endocrine system consists of glands and tissues that produce hormones regulating functions such as growth, metabolism, reproduction, stress responses, sleep, and blood-glucose control.

Artificial endocrine technologies may include:

Hormone-replacement medicines and long-acting hormone-delivery systems.

Insulin pumps and automated glucose-monitoring systems.

Implantable devices that release hormones or other therapeutic substances.

Digital systems that use biological measurements to recommend or adjust treatment.

Experimental technologies that regulate endocrine activity through electrical, genetic, or other biological interventions.

The central governance question is:

Who should be legally responsible when an artificial system monitors, modifies, or controls a person's hormonal functions and causes harm, violates autonomy, or makes an unsafe treatment decision?

The proposed doctrine addresses this question through a combination of regulatory oversight, patient rights, technical safety, accountability, and judicial review.

2. Core principles of the proposed doctrine

1. Bodily integrity and autonomy

Patients must retain meaningful control over interventions affecting their hormonal functions, subject to lawful emergency treatment and other recognized exceptions. Informed consent should explain material risks, alternatives, reversibility, and foreseeable long-term effects.

2. Clinical safety and proportionality

The greater the potential severity, duration, or irreversibility of an intervention, the stronger the justification for testing, monitoring, and safeguards should be.

3. Accountability across the technology lifecycle

Manufacturers, prescribing clinicians, healthcare institutions, software developers, and regulators may have different duties. Responsibility should depend on their conduct, control, applicable law, and contribution to the harm.

4. Hormonal data protection

Hormone levels, reproductive information, metabolic measurements, and related health records require appropriate confidentiality, security, and lawful processing.

5. Regulatory transparency and review

Approval decisions, safety warnings, adverse-event investigations, and restrictions on access to treatment should follow applicable legal procedures and be open to appropriate review.

3. Important Indian case laws

The doctrine can be applied through existing judicial decisions. The cases below do not establish a separate artificial endocrine doctrine; rather, they supply the legal principles from which such a framework can be developed.

Case 1: Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

Supreme Court of India

Facts: The patient underwent a diagnostic procedure, during which the doctor performed additional surgery without obtaining the patient's consent. The additional procedure involved removing reproductive organs, resulting in serious and irreversible consequences, including the need for hormone-replacement therapy.

Indian Kanoon

+1

Legal issue: Can a doctor undertake a materially different or additional intervention without the patient's consent merely because the doctor believes it would benefit the patient?

Decision and principle: The Supreme Court explained that valid consent requires capacity, voluntariness, and adequate information about the proposed procedure. Consent to one procedure does not ordinarily authorize an unrelated or additional procedure. A limited exception exists where further intervention is necessary to save life or preserve health and postponement would be unreasonable.

Application to artificial endocrine governance: This is a particularly relevant precedent because the case itself concerned reproductive-organ removal and subsequent hormone-replacement therapy.

For an artificial endocrine intervention, the judgment supports the following safeguards:

Obtain consent for the actual treatment or procedure proposed.

Explain substantial risks, expected benefits, and available alternatives.

Do not treat consent to monitoring as blanket authorization for hormonal intervention.

Do not permit a device or algorithm to expand the scope of treatment without appropriate clinical authorization.

The case therefore provides a strong foundation for the proposed doctrine's principle of bodily autonomy and consent.

Indian Kanoon

+1

Case 2: Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651

Medical negligence and consumer protection

Facts: The case concerned whether medical practitioners and hospitals providing medical treatment fall within the consumer-protection framework.

Legal principle: The Supreme Court held that qualifying medical services for consideration fall within the scope of consumer-protection law, subject to the distinctions explained in the judgment, including the treatment of services provided entirely free of charge.

Application: If a patient suffers harm because a hospital negligently administers hormone therapy, improperly operates a hormone-delivery device, or fails to provide an appropriate medical service, consumer-protection remedies may be available where the applicable statutory conditions are met.

Under India's Consumer Protection Act, 2019, product liability and deficiency-in-service provisions may also be relevant, depending on the facts and the parties involved. The precise route depends on the nature of the claim and applicable law.

Indian Kanoon

+1

Case 3: K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1

Legal issue: Does the Constitution protect privacy as a fundamental right?

Decision: The Supreme Court recognized privacy as a constitutionally protected fundamental right under Article 21 and the broader framework of Part III of the Indian Constitution.

Application to artificial endocrine governance: Endocrine technologies may collect highly revealing information, including hormone concentrations, reproductive-health indicators, metabolic patterns, and longitudinal physiological data.

A governance framework based on Puttaswamy should therefore consider:

Lawful and appropriately limited collection of biological data.

Protection against unauthorized disclosure or access.

Appropriate restrictions on secondary use, profiling, and commercial exploitation.

Proportionate safeguards for sensitive health information.

This does not mean that every use of endocrine data requires separate constitutional consent in every circumstance. The legality of a particular processing activity depends on the applicable law, purpose, safeguards, and circumstances.

Case 4: Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

Legal issue: What standard governs criminal liability for medical negligence?

Decision: The Supreme Court discussed the distinction between civil and criminal medical negligence and emphasized that criminal prosecution of a medical professional requires a substantially higher threshold than a mere error of judgment or ordinary civil negligence.

Application: Suppose a clinician uses an automated endocrine-management system and a patient suffers a severe hormonal complication. The outcome alone does not establish criminal negligence. Investigators must examine the clinician's conduct, the applicable professional standard, causation, and the requirements of the relevant criminal offence.

The same distinction is important when a hospital deploys an inadequately validated algorithm or ignores known device warnings: the facts must establish the elements of the particular civil or criminal claim.

Case 5: Indian Medical Association v. Union of India, (2011) 7 SCC 179

Legal significance: This Supreme Court decision addressed aspects of the regulatory framework governing medical education and professional standards. It is relevant as a broader illustration of the relationship between professional regulation and public protection, rather than as a direct ruling on endocrine technology.

Application: Governance of artificial endocrine systems should not rely exclusively on manufacturers' assurances. Appropriate professional standards, clinical competence, and institutional oversight remain important when new technologies are introduced into patient care.

Indian Kanoon

Case 6: Yash Charitable Trust v. Union of India, Supreme Court of India, judgment dated 30 January 2026

Legal issue: Can a patient's consent validate an experimental treatment when adequate scientific evidence about its safety and effectiveness is absent?

Principle: The Supreme Court discussed the requirements of valid informed consent and the ethical problems associated with presenting unproven stem-cell treatments as established therapies. The judgment reinforces that voluntary consent alone does not cure deficiencies in the information needed for a meaningful treatment decision.

Sci API

+1

Application: The same reasoning is relevant by analogy to experimental endocrine implants, novel hormone-regulating systems, and unvalidated biological control technologies. Patients should be informed about the experimental status of a treatment, the evidence supporting it, the known uncertainties, and the alternatives.

This does not mean that every experimental endocrine intervention is unlawful. Properly authorized research may be permissible under the applicable clinical-trial and ethics framework.

4. Statutory framework governing artificial endocrine technologies in India

The proposed doctrine would operate through existing legislation and regulatory institutions rather than replace them.

India's Central Drugs Standard Control Organisation identifies medical devices as being regulated under the Drugs and Cosmetics Act and Medical Devices Rules. Whether a particular endocrine technology qualifies as a drug, device, combination product, or another regulated category depends on its intended purpose and characteristics.

CDSCO

+2

5. Manufacturer liability and technological failures

Consider a hypothetical automated insulin-delivery system that incorrectly interprets sensor data and delivers an excessive dose, causing severe hypoglycaemia.

The proposed doctrine would require an investigation into several distinct questions:

Design defect: Was the system designed with inadequate safeguards against foreseeable dosing errors?

Manufacturing defect: Did the particular device depart from its intended specifications?

Warning failure: Were users adequately informed about risks, limitations, and emergency procedures?

Clinical negligence: Did the treating professional fail to prescribe, configure, monitor, or respond to the system appropriately?

Institutional failure: Did the hospital ignore known safety warnings or fail to train staff?

Causation: Did the identified defect or negligent act actually contribute to the injury?

Under the Consumer Protection Act, 2019, product liability may apply to qualifying claims against manufacturers, product sellers, and product service providers. The statutory conditions and defences must be examined in each case.

National Consumer Helpline - NCH

+1

The existence of an algorithm does not automatically transfer all responsibility to the manufacturer, nor does the involvement of a clinician automatically absolve the manufacturer. Liability depends on the applicable legal rules and evidence.

6. Administrative accountability and judicial review

Government authorities may need to assess whether a hormone-regulating technology has adequate evidence of safety, whether its marketing complies with applicable law, and whether new risks justify regulatory action.

The proposed doctrine would support the following administrative safeguards:

Evidence-based authorization and risk classification.

Clear reasons for significant regulatory decisions.

Monitoring and reporting of adverse events.

Appropriate procedures for recalls, safety notices, and restrictions.

Review of conflicts of interest and misleading therapeutic claims.

Judicial scrutiny of unlawful or arbitrary administrative action.

A regulator's failure to prevent every adverse outcome does not automatically establish legal liability. A claimant would need to establish an applicable legal duty, breach, causation, and any other required elements.

7. Application to major endocrine-governance problems

A. Artificial hormonal enhancement

Technologies intended to increase growth, alter metabolism, or enhance physical performance raise questions about medical necessity, evidence of long-term harm, consent, misleading advertising, and access by minors.

B. Reproductive and fertility interventions

Artificial reproductive-hormone systems may affect fertility, menstrual cycles, or reproductive capacity. Samira Kohli is especially relevant to consent and unauthorized interventions affecting reproductive organs.

C. Autonomous endocrine algorithms

A system that changes a treatment recommendation automatically should have appropriate validation, human oversight where necessary, traceable decisions, and safeguards against unsafe outputs.

D. Long-term implants

Implantable hormone-delivery systems raise additional questions about maintenance, withdrawal of treatment, removal procedures, post-market monitoring, and responsibility when the device cannot be safely deactivated.

E. Discrimination and privacy

Employers, insurers, educational institutions, and other organizations may misuse endocrine data to infer reproductive status, health risks, or behavioural characteristics. Such practices require scrutiny under the applicable privacy, equality, employment, and sector-specific laws.

8. Proposed legal test for applying the doctrine

A court, regulator, or ethics committee could use the following analytical test when assessing a disputed artificial endocrine intervention. This is a proposed framework, not an existing binding judicial test.

Legality: Was the technology lawfully developed, authorized, supplied, and used?

Scientific validity: Is there adequate evidence supporting the claimed purpose, safety, and effectiveness?

Consent and autonomy: Did the patient receive appropriate information and freely authorize the intervention?

Proportionality: Are the expected benefits reasonably proportionate to the risks, particularly where effects may be irreversible?

Accountability: Can the relevant decisions, system behaviour, clinical actions, and safety responses be investigated?

Remedies: Are appropriate mechanisms available for compensation, correction, withdrawal, reporting, and regulatory review?

9. Conclusion

The Artificial Endocrine Governance Doctrine is best understood as a proposed interdisciplinary legal framework connecting biotechnology regulation, medical negligence, constitutional rights, product liability, and digital-health governance.

Its strongest Indian legal foundations include Samira Kohli on bodily autonomy and consent, V.P. Shantha on medical services and consumer protection, Puttaswamy on privacy, and Jacob Mathew on medical negligence. The 2026 Yash Charitable Trust judgment also offers relevant guidance concerning informed consent and unproven treatments.

The central proposition is that the ability to regulate a person's hormonal functions technologically must not eliminate the person's legal rights or the accountability of those who design, authorize, prescribe, or operate the technology.

The proposed doctrine may help courts and lawmakers address emerging problems, but its individual principles must be grounded in the actual constitutional provisions, legislation, regulations, and binding precedents applicable to each dispute.